Top of this page
Skip navigation, go straight to the content

This section is intended for media and financial analysts
Newsroom Press Releases

Financière de Tubize strengthens its shareholding in UCB

Brussels (Belgium), February 9, 2007 - 6:00 PM CET - Financière de Tubize S.A., UCB's reference shareholder, has announced today that Financière de Tubize and a group of long term investors have acquired 13.89 million shares of UCB (7.58% of UCB issued share capital) from the Schwarz family. The Schwarz family is committed to retaining its remaining 9.88 million shares of UCB (5.39% of UCB issued share capital) until at least June 2010.


Roch Doliveux, Chief Executive Officer, UCB, commented "UCB highly appreciates the enhanced commitment and confidence of Financière de Tubize and welcomes the endorsement of these new long term shareholders."

A copy of Financière de Tubize's press release is attached.

About UCB

UCB ( is a leading global biopharmaceutical company dedicated to the research, development and commercialisation of innovative pharmaceutical and biotechnology products in the fields of central nervous system disorders, allergy/respiratory diseases, immune and inflammatory disorders and oncology - UCB focuses on securing a leading position in severe disease categories. Employing over 8,300 people in over 40 countries, UCB achieved revenue of 2.3 billion euro in 2005. UCB is listed on the Euronext Brussels Exchange. Worldwide headquarters are located in Brussels, Belgium.


Further information:

Jean-Christophe Donck

Mareike Mohr

Vice President,

Associate Director,

Corporate Communications & Investor Relations     

Investor Relations

Tel. +32 2 559 9346

Tel. +32 2 559 9264

Stay up-to-date on the latest news and information from UCB